Sharp Therapeutics Corp. (TSXV:SHRX)

Canada flag Canada · Delayed Price · Currency is CAD
2.200
0.00 (0.00%)
At close: Feb 6, 2026
Market Cap66.17M
Revenue (ttm)n/a
Net Income-4.63M
EPS-0.15
Shares Out30.08M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,600
Average Volume3,192
Open2.200
Previous Closen/a
Day's Range2.200 - 2.200
52-Week Range0.230 - 5.000
Beta-1.10
RSI40.42
Earnings DateApr 24, 2026

About Sharp Therapeutics

Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies, enables discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a proprietary IP-protected analytics platform that captures all data for all AlloChem compounds in all CoreX assays. Sharp Therapeutics Corp. is headquartered in Pittsburgh, Pennsylvania. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Scott Sneddon
Country Canada
Stock Exchange TSX Venture Exchange
Ticker Symbol SHRX
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements